Spis treści
Gotowa bibliografia na temat „Peak width of skeletonized mean diffusivity (PSMD)”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Peak width of skeletonized mean diffusivity (PSMD)”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Peak width of skeletonized mean diffusivity (PSMD)"
Jochems, Angela C. C., Susana Muñoz Maniega, Una Clancy, Daniela Jaime Garcia, Carmen Arteaga, Will Hewins, Rachel Penman i in. "Associations of Peak-Width Skeletonized Mean Diffusivity and Post-Stroke Cognition". Life 12, nr 9 (31.08.2022): 1362. http://dx.doi.org/10.3390/life12091362.
Pełny tekst źródłaVinciguerra, C., A. Giorgio, J. Zhang, I. Di Donato, M. L. Stromillo, R. Tappa Brocci, A. Federico, M. T. Dotti i N. De Stefano. "Peak width of skeletonized mean diffusivity (PSMD) as marker of widespread white matter tissue damage in multiple sclerosis". Multiple Sclerosis and Related Disorders 27 (styczeń 2019): 294–97. http://dx.doi.org/10.1016/j.msard.2018.11.011.
Pełny tekst źródłaMayer, Carola, Felix L. Nägele, Marvin Petersen, Maximilian Schell, Ghazal Aarabi, Thomas Beikler, Katrin Borof i in. "Association between Coffee Consumption and Brain MRI Parameters in the Hamburg City Health Study". Nutrients 15, nr 3 (28.01.2023): 674. http://dx.doi.org/10.3390/nu15030674.
Pełny tekst źródłaRaposo, N., M. C. Zanon Zotin, D. Schoemaker, L. Xiong, P. Fotiadis, A. Charidimou, M. Pasi i in. "Peak Width of Skeletonized Mean Diffusivity as Neuroimaging Biomarker in Cerebral Amyloid Angiopathy". American Journal of Neuroradiology 42, nr 5 (4.03.2021): 875–81. http://dx.doi.org/10.3174/ajnr.a7042.
Pełny tekst źródłaKang, Sujin, Dong Ah Lee, Jun Won Lee, Ho-Joon Lee i Kang Min Park. "White matter changes in patients with narcolepsy type 2: Peak width of skeletonized mean diffusivity study". Sleep Medicine 129 (maj 2025): 14–19. https://doi.org/10.1016/j.sleep.2025.02.020.
Pełny tekst źródłaJarholm, Jonas, Sandra Tecelão, Lene Pålhaugen, Atle Bjørnerud, Bjørn Eivind Kirsebom, Tormod Fladby i Per Selnes. "Peak width of skeletonized mean diffusivity as a biomarker of small vessel disease in predementia Alzheimer's disease". Cerebral Circulation - Cognition and Behavior 6 (2024): 100303. http://dx.doi.org/10.1016/j.cccb.2024.100303.
Pełny tekst źródłaPark, Kang Min, Keun Tae Kim, Dong Ah Lee i Yong Won Cho. "Small vessel disease in patients with restless legs syndrome evidenced by elevated peak width of skeletonized mean diffusivity". Journal of the Neurological Sciences 467 (grudzień 2024): 123310. http://dx.doi.org/10.1016/j.jns.2024.123310.
Pełny tekst źródłaLam, Bonnie Yin Ka, Kam Tat Leung, Brian Yiu, Lei Zhao, J. Matthijs Biesbroek, Lisa Au, Yumi Tang i in. "Peak width of skeletonized mean diffusivity and its association with age‐related cognitive alterations and vascular risk factors". Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 11, nr 1 (grudzień 2019): 721–29. http://dx.doi.org/10.1016/j.dadm.2019.09.003.
Pełny tekst źródłaXu, Man, Kangkang Xue, Xueqin Song, Yong Zhang, Jingliang Cheng i Junying Cheng. "Peak width of skeletonized mean diffusivity as a neuroimaging biomarker in first-episode schizophrenia". Frontiers in Neuroscience 18 (23.09.2024). http://dx.doi.org/10.3389/fnins.2024.1427947.
Pełny tekst źródłaJarholm, Jonas Alexander, Sandra Tecelao, Lene Pålhaugen, Bjørn‐Eivind Kirsebom, Atle Bjornerud, Tormod Fladby i Per Selnes. "The role of Peak width Skeletonized Mean Diffusivity in AD disease progression". Alzheimer's & Dementia 20, S8 (grudzień 2024). https://doi.org/10.1002/alz.095692.
Pełny tekst źródłaRozprawy doktorskie na temat "Peak width of skeletonized mean diffusivity (PSMD)"
Saba, Yasaman. "Déterminants génétiques des marqueurs IRM du vieillissement vasculaire cérébral". Electronic Thesis or Diss., Bordeaux, 2024. http://www.theses.fr/2024BORD0466.
Pełny tekst źródłaOver the last century, life expectancy has increased dramatically, contributing to a sharp increase in the number of patients with common neurological disease, especially stroke and dementia. Mounting evidence suggests that early life factors, including genetic factors, play a crucial role in the occurrence of such diseases. Cerebral small vessel disease (cSVD) is a major cause of stroke, cognitive decline and dementia. cSVD is most often covert, detectable on brain images in the absence of clinical manifestations. Brain magnetic resonance imaging (MRI) markers of cSVD, which can be measured non-invasively in large population, can provide crucial insights into the cause of late-life neurological diseases. White matter hyperintensities (WMH), lacunes, cerebral microbleeds, and perivascular spaces are the most commonly studied MRI-markers of cSVD, while diffusion tensor imaging (DTI) offers new opportunity to explore susceptibility to cSVD across the lifespan. Deciphering these genetic risk factors of cSVD, including in early life, is a powerful tool to decipher molecular mechanisms leading to this disease. In this thesis, we explored the genetic determinants of MRI-markers of cSVD in the general population across the lifespan, by conducting large collaborative meta-analyses of genome-wide association studies (GWAS) in up to 58,403 participants from the general population. First, we conducted a GWAS of WMH stratified on hypertension status. Our results shed new light into modifying effects of high blood pressure on genetic susceptibility to WMH. Second, we examined the genetic underpinnings of an emerging DTI marker, peak width of skeletonized mean diffusivity (PSMD), by conducting the first GWAS of PSMD, across the lifespan. We identified up to 25 novel genetic risk loci for PSMD, with good effect size correlation across European and East-Asian ancestries. Additionally, in a whole-exome association study (derived from whole exome sequencing), rare variants and burden of rare loss-of-function or singleton variants in 4 different genes were associated with PSMD. Genetically determined larger volume of WMH was associated with higher PSMD from early childhood to older age. Moreover, common PSMD risk loci were enriched in genes expressed in fetal brain endothelial cells. In conclusion, this work provides new insights into complex genomics of cSVD across the lifespan, across ancestries, and in interaction with hypertension, the most common risk factor of cSVD. These results are informative for the development of efficient preventive and therapeutic strategies for cSVD and its complications, a major public health challenge